Providing Potentially Incompatible Plasma during Bleeding Emergencies

Please note: AABB reserves the right to make updates to this program.

Live Program Date: Wednesday, February 7, 2018 - On-Demand Available
Master Program Number: 18EL-310 (see program format numbers below under Registration)

Educational Track: Technical/Clinical
Topic: Transfusion Medicine
Intended Audience: CFOs, Hospitals, Hospitals Blood Banks, Laboratory Staff, Medical Directors, Physicians, Resident/Fellow, Students (MD, MT, SBB), Technologists
Teaching Level: Intermediate

Director/Moderator: Nancy M. Dunbar, MD, Medical Director, Blood Bank, Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Speakers: Mark H. Yazer, MD, Professor of Pathology, University of Pittsburgh, Medical Director, RBC Serology Reference Laboratory, Centralized Transfusion Service, and Associate Medical Director, Centralized Transfusion Service, University of Pittsburgh, Institute for Transfusion Medicine, Pittsburgh, PA; Sarah Harm, MD, MS, Assistant Professor, Department of Pathology & Laboratory Medicine, Medical Director, Blood Bank/Transfusion Medicine, University of Vermont Medical Center, Burlington, VT

Learning Objectives

After participating in this educational activity, participants should be able to:

  • Describe how uncrossmatched, low titer, group O, cold stored, whole blood and group A plasma are being used for trauma resuscitation in adult and pediatric civilian hospitals.
  • Review results of recent studies examining the safety of administering uncrossmatched, low titer, group O, cold-stored, whole blood and group A plasma during civilian trauma resuscitation.
  • Examine currently available data on the prevalence of high titer units by donor blood group and variations in anti-A and/or anti-B titers in the same donor over time.

Program Description

Transfusions play a key role in preventing deaths in traumatic shock and in other massively bleeding patients. The use of emergency issued group A plasma and uncrossmatched group O whole blood in patients without a valid ABO group is becoming increasingly common in the USA. Preliminary data supports the safety of these practices. It remains unclear if low titer products should always be provided and a universally agreed upon threshold that would qualify as “low titer” has not been established. Additional questions include whether the donors' anti-A and/or anti-B titers change over time and whether repeated titer measurements on the same donor are required to ensure that each donation produces a low titer product. 


   Program #
Single Viewer: On-Demand Register18EL-310-4035
Group Viewing: On-Demand Register18EL-310-8035

Continuing Education Credit

AABB designates both the live and on-demand version of this eCast each eligible for 1 continuing education credit/contact hour for Physicians, General Participation, California Nurse, California Lab Personnel and Florida Lab Personnel. The number and type of credits awarded for this program (both live and on-demand) was determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.

Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.

Speaker Biographies

Dr. Mark Yazer graduated from medical school at the university of Ottawa in 2000 and completed his residency in hematological pathology at the University of Alberta in 2004.  He is currently a Professor of Pathology at the University of Pittsburgh, and the Medical Director of the RBC serology laboratory at the centralized transfusion service in Pittsburgh, one of the largest transfusion services in North America.  He is also an adjunct professor of clinical immunology at the University of Southern Denmark.  He has published over 150 peer reviewed papers, and is an associate editor of the journal Transfusion Medicine and the journal Hematology.  He is on the editorial board of 4 other journals.  He is the chairman of the AABB's molecular testing standards unit, and the co-chairman of the AABB/THOR working group.  He has received grant funding from the American National Institutes of Health, the American Department of Defense, and the American military based DARPA group.  He is currently a co-principle investigator of NIH R01 and R34 grants and is a collaborator on two department of defense grants.  He is on the scientific advisory/speakers board of 7 corporations, and he has given more than 200 lectures on his research worldwide.  His research interests include patient blood management, blood utilization in trauma, and electronic enhancements for patient safety.

Dr. Sarah Harm is the medical director of the Blood Bank at University of Vermont Medical Center in Burlington, VT.  She completed her fellowship in Blood Bank/Transfusion Medicine in Pittsburgh, PA at the Institute for Transfusion Medicine.  Sarah is originally from Nazareth, PA and spent many years between Boston, MA and Philadelphia, PA for education and work in the pharmaceutical industry.